Activation of the coagulation system in cancerogenesis and metastasation

W. Z. Xie, M. Leibl, M. R. Clark, P. Dohrmann, T. Kunze, F. Gieseler*

*Korrespondierende/r Autor/-in für diese Arbeit
7 Zitate (Scopus)


The activation of the coagulation system in cancer patients is a well-known phenomenon responsible for recurrent clinical problems. A number of fascinating molecular mechanisms have been recognized showing that the tumor not only activates the coagulation system, but vice versa, activated coagulation proteins are able to induce molecular effects in tumor cells. The molecular basis is the expression of defined membrane receptors by tumor cells that are activated, for example, by thrombin. As the liberation of thrombin from prothrombin is one of the key events in coagulation, it's impact upon biological processes, such as cancerogenesis and metastasation, seems to be a regular pathophysiological consequence. These perceptions are not only interesting for the comprehension of cancerogenesis, metastasation, and clinical phenomena, but they also have a high impact upon modern strategies of tumor therapy. Especially, the development of clinically useful coagulation inhibitors, such as modern low molecular weight heparins or melagatran, created the possibility of therapies that combine cell biological approaches with apoptosis-inducing principals such as chemotherapy. Several clinical studies that demonstrate the implication of these strategies have already been published recently. In this article the cell biological basics for these approaches are reviewed.

ZeitschriftBiomedicine and Pharmacotherapy
Seiten (von - bis)70-75
PublikationsstatusVeröffentlicht - 04.2005


Untersuchen Sie die Forschungsthemen von „Activation of the coagulation system in cancerogenesis and metastasation“. Zusammen bilden sie einen einzigartigen Fingerprint.